Inhibition of tau neuronal internalization using anti-tau single domain antibodies

In Alzheimer's disease, tau pathology spreads across brain regions as the disease progresses. Intracellular tau can be released and taken up by nearby neurons. We evaluated single domain anti-tau antibodies, also called VHHs, as inhibitors of tau internalization. We identified three VHH inhibitors of tau uptake: A31, H3-2, and Z70<sub>mut1</sub>. These VHHs compete with the membrane protein LRP1, a major receptor mediating neuronal uptake of tau. A31 and Z70<sub>mut1</sub> bind to microtubule binding domain repeats, which are involved in the interaction with LRP1. VHH H3-2 is the only VHH from our library that reduces the internalization of both monomeric tau and tau fibrils. VHH H3-2 binds a C-terminal tau epitope with high affinity. Its three-dimensional structure in complex with a tau peptide reveals a unique binding mode as a VHH-swapped dimer. These anti-tau VHHs are interesting tools to study tau prion-like propagation in tauopathies and potentially develop novel biotherapies.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-04-02
DOI
https://doi.org/10.1038/s41467-025-58383-4
Citations
13
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
15.14

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inhibition of tau neuronal internalization using anti-tau single domain antibodies

Xavier Hanoulle, Morvane Colin, Jean‐Christophe Rain, Justine Mortelecque et al.
13 citations
Nature Communications
Alzheimer's disease research and treatments
15.14
article

Inhibition of tau neuronal internalization using anti-tau single domain antibodies

Xavier Hanoulle, Morvane Colin, Jean‐Christophe Rain, Justine Mortelecque, Clément Danis, Isabelle Landrieu, Thomas Bouillet, Elian Dupré, Luc Buée, François‐Xavier Cantrelle, Camille Lefebvre, Marine Denéchaud, Marine Nguyen
article en
13 citations

Abstract

In Alzheimer's disease, tau pathology spreads across brain regions as the disease progresses. Intracellular tau can be released and taken up by nearby neurons. We evaluated single domain anti-tau antibodies, also called VHHs, as inhibitors of tau internalization. We identified three VHH inhibitors of tau uptake: A31, H3-2, and Z70<sub>mut1</sub>. These VHHs compete with the membrane protein LRP1, a major receptor mediating neuronal uptake of tau. A31 and Z70<sub>mut1</sub> bind to microtubule binding domain repeats, which are involved in the interaction with LRP1. VHH H3-2 is the only VHH from our library that reduces the internalization of both monomeric tau and tau fibrils. VHH H3-2 binds a C-terminal tau epitope with high affinity. Its three-dimensional structure in complex with a tau peptide reveals a unique binding mode as a VHH-swapped dimer. These anti-tau VHHs are interesting tools to study tau prion-like propagation in tauopathies and potentially develop novel biotherapies.

Nature CommunicationsVol. 16(1)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université de Lille (FR), Institut Pasteur de Lille (FR), Centre Hospitalier Universitaire de Lille (FR), Hybrigenics (France) (FR), Lille Neurosciences & Cognition (FR)
Alzheimer's Association, Université de Lille, European Commission, Agence Nationale de la Recherche, Association France Alzheimer, Centre National de la Recherche Scientifique
Good health and well-being
Openalex Percentile: Top 1%
Alzheimer's disease research and treatments
15.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.